PathAI Stock

pathai.comHealthcare / Digital HealthFounded: 2016Funding to Date: $255.49MM

PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient. This company was founded by Aditya Khosla and Andrew Beck in 2016 and is headquartered in Greater Boston Area, NE. PathAI services solve challenging pathology problems faced by the research and pharmaceutical industry.

Register To Buy and Sell Shares

For more details on financing and valuation for PathAI, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access PathAI’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like PathAI.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Andrew Beck
Co-Founder & Chief Executive Officer
Aditya Khosla
Co-Founder & Chief Technology Officer
Tiffany Freitas
Chief Business Officer
Andy Moffit
Chief People Officer

Board Members

Stanley Lapidus
Daktari Diagnostics

Frequently Asked Questions About PathAI’s Stock

Can you buy PathAI’s stock?
PathAI is not publicly traded on NYSE or NASDAQ in the U.S. To buy PathAI’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell PathAI’s stock?
Yes, you can sell stock of a private company like PathAI. Forge can help you sell your PathAI stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is PathAI’s stock price?
PathAI is a privately held company and therefore does not have a public stock price. However, you may access PathAI’s private market stock price with Forge Data.
What is PathAI’s stock ticker symbol?
PathAI does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

PathAI Announces AISight Support of DICOM Standards and Commits to Being a Leader in Integrated Enterprise Image Architecture and Strategy
PathAI, a technology company specializing in AI-powered pathology solutions, has announced support for DICOM standards and aims to be a leader in integrated enterprise image architecture and strategy. This development marks a significant step towards PathAI's vision of interoperable pathology systems. The firm is also planning to launch its DICOMweb API, which will enhance its integration with organizations’ enterprise image management and archive strategies.
PathAI Announces New NASH/MASH Advisory Network to Guide Evidence Generation and Regulatory Strategy for AI-Powered Digital Pathology Product Development
PathAI, a precision pathology solutions provider, has announced the creation of a NASH/MASH advisory network. The network, comprising international experts, will guide the development of AI-powered digital pathology products to improve outcomes for those with non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH). The advisory network's first meeting took place in September and will meet quarterly.
Updated on: Feb 27, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.